[show abstract]
[hide abstract]
ABSTRACT: It is not known whether high-dose statins can reduce the excess burden (and consequent adverse cardiovascular outcomes) of coronary artery disease in patients with metabolic syndrome compared with those without metabolic syndrome. The results of our study suggest that high-dose simvastatin may be required to reduce excess events in very high-risk cohorts with metabolic syndrome.
The American Journal of Cardiology 06/2006; 97(10):1487-9. · 3.37 Impact Factor
